Regional Disparities in the Uptake of Differentiated Influenza Vaccines

Salaheddin M. Mahmud MD PhD1,*, Gurpreet Pabla BSc1, Christiaan H. Righolt PhD1, Geng Zhang, MSc1, Matthew M. Loiacono PhD2, Edward Thommes PhD3 4, Heidi Kabler MD5 6 7, Ayman Chit PhD8 9
1 Vaccine and Drug Evaluation Centre, Department of Community Health Sciences, University of Manitoba, 337–750 McDermot Avenue, Winnipeg, MB, R3E 0T5 Canada
2 Global Medical Evidence Generation, Sanofi, 1 Discovery Dr, 18370, Swiftwater, PA, United States
3 Global Modeling Epidemiology and Data Science, Sanofi, 1755 Steeles Ave W, North York, ON M2R 3T4, Canada
4 Department of Mathematics & Statistics, University of Guelph, 50 Stone Road East, Guelph, Ontario N1G 2W1, Canada
5 US Medical Affairs, Sanofi, 1 Discovery Dr, 18370, Swiftwater, PA United States
6 MountainView Program in Emergency Medicine, MountainView Hospital, 3100 N Tenaya Way, 89128, Las Vegas, NV United States
7 Reno School of Medicine, University of Nevada, Reno, 89557, NV, United States
8 Global Medical, Sanofi, 14 Espa. Henry Vallée, 69007 Lyon, France
9 Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
*Address for correspondence:
Dr. Salaheddin Mahmud, MD PhD FRCPC
Professor and Director, Vaccine and Drug Evaluation Centre, Department of Community Health Sciences, University of Manitoba,
337 - 750 McDermot Avenue, Winnipeg, Manitoba, R3E 0T5 Canada
Salah.Mahmud@gmail.com
Keywords: influenza; seasonal influenza vaccine; high-dose influenza vaccine; inequities; disparities; Enhanced influenza vaccines.

FUNDING STATEMENT

This collaborative study with the University of Manitoba was funded by Sanofi (US).

ETHICS APPROVAL STATEMENT

The University of Manitoba Research Ethics Board approved this study.

CONFLICTS OF INTEREST DISCLOSURE

SMM received research funding from Assurex, GSK, Merck, Pfizer, Roche and Sanofi for unrelated studies and is/was a member of advisory boards for GSK, Merck, Sanofi and Seqirus. CHR has received an unrestricted research grant from Pfizer for an unrelated study. MML, ET, HK, and AC are employees of Sanofi and may hold shares and/or stock options in the company.

AUTHOR CONTRIBUTIONS

Salaheddin Mahmud : Conceptualization, Methodology, Formal analysis, Investigation, Resources, Writing - Original Draft, Visualization, Supervision, Funding acquisition; Gurpreet Pabla BSc: Software, Formal analysis, Investigation, Data Curation, Writing - Review & Editing, Visualization; Christiaan Righolt : Methodology, Validation, Investigation, Writing - Review & Editing, Project administration; Geng Zhang MSc : Software, Data Curation, Writing - Review & Editing, Visualization; Matthew M. Loiacono : Investigation, Resources, Data Curation, Writing - Review & Editing, Project administration; Heidi Kabler : Conceptualization, Investigation, Writing - Review & Editing, Funding acquisition; Edward Thommes : Conceptualization, Investigation, Writing - Review & Editing, Funding acquisition; Ayman Chit : Conceptualization, Investigation, Writing - Review & Editing, Funding acquisition

DATA AVAILABILITY STATEMENT

Data used in this article was derived from administrative health and social data as a secondary use. The data was provided under specific data sharing agreements only for approved use. The original source data is not owned by the researchers and as such cannot be provided to a public repository. Source data specific to this article may be accessed with the consent of the data provider, along with the required privacy and ethical review bodies.